Neurological biomarkers are measurable indicators of some biological states or conditions related to neurodegenerative disorders, mood disorders, and other brain diseases. Neurological biomarkers find applications in the diagnosis and drug development of neurological disorders including Alzheimer's disease, Parkinson’s disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, and others. They help monitor disease progression, drug effects and also aid in clinical trials for novel therapies. The rising prevalence of neurological disorders worldwide is mainly fueling the demand for advanced diagnostic tools such as neurological biomarkers.
The Global Neurological Biomarkers Market is estimated to be valued at US$ 13,609.32 Mn in 2024 and is expected to exhibit a CAGR of 5.9% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the Neurological Biomarkers market are Knauf Gips KG, LafargeHolcim, National Gypsum Company, Saint-Gobain Group, Yoshino Gypsum Co., Ltd., ACG Materials, Anhydritec, BNZ Materials Inc., American Gypsum, Gyptec Iberica. These key players are investing in R&D activities to develop advanced blood and imaging biomarkers for quick diagnosis of neurological disorders.
In terms of opportunities, shifting preference towards personalized medicine for effective treatment of neurological disorders along with growing funding by government and private organizations for neurological biomarker research will create lucrative opportunities for market players in the forecast period.
Globally, North America dominated the neurological biomarkers market in 2024 due to growing awareness regarding advanced treatment options and early diagnosis of neurological diseases. However, Asia Pacific region is anticipated to witness highest growth in the coming years owing to rising elderly population, increases healthcare investments, and growing per capita income.
Market drivers: Rising prevalence of neurological disorders is a major driver of this market. According to WHO estimates, over 1 billion people suffer from neurological disorders worldwide. Increasing adoption of biomarkers to facilitate early diagnosis and monitor disease progression is also propelling market growth.
Market restraints: However, high cost of neurological biomarker tests and lack of reimbursements policies may restrain the market growth up to some extent. Dearth of skilled professionals for managing sophisticated neurological diagnostic equipments is another challenge for industry players.
Segment Analysis
Neurological Biomarkers Size can be segmented into proteomics, genomics, imaging, and other segments. The proteomics segment dominated the market in 2024 due to increasing adoption of proteomics technologies in biomarker research and diagnostic applications. Proteomics allows for high-throughput protein analysis and biomarker identification which contributes to its large market share.
Global Analysis
North America region dominated the global Neurological Biomarkers market in 2024 due to increasing R&D activities in neurological disease diagnostics and presence of key pharmaceutical companies and research organizations in the region. The Asia Pacific region is expected to grow at the highest CAGR during the forecast period owing to rising healthcare spending, increasing research on neurodegenerative diseases, and growing base of pharmaceutical companies establishing manufacturing and research facilities in countries like China and India. Key players in the Neurological Biomarkers market are focusing on geographic expansion plans and product innovation initiatives to gain higher market share and drive long term growth.
For More Details On The Report, Read: https://www.newswirestats.com/the-rise-of-neurological-biomarkers-in-precision-medicine/
Explore More Related Trending Articles: https://coolbio.org/system-on-a-chip-soc-the-future-of-electronics/
Comments
0 comment